Oruka Therapeutics, Inc. (ORKA)

SEC filing

Oruka Therapeutics, Inc.

ORKA · CIK 907654

4 · Oct 20, 2026 · General Counsel Quinlan Paul T sold 9,000 shares at $78.53/share ($706.7K); exercised options for 18K shares

General Counsel Quinlan Paul T sold 9,000 shares at $78.53/share ($706.7K); exercised options for 18K shares

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

xslF345X06/form4.xmlSEC.gov

Graphics and non-inline formats (not embedded below).

4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESform4.xml
Open SEC.gov